We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study
Read MoreHide Full Article
Medical device major Medtronic plc (MDT - Free Report) is focusing on expanding its core Coronary and Structural Heart business. Keeping in line with this, the company recently announced a global randomized clinical trial to evaluate one-month dual antiplatelet therapy (DAPT) in patients implanted with the Resolute Onyx Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI) procedures.
DAPT is a combination of aspirin and anti-clotting medication. Notably, Resolute Onyx DES is the first DES which works on the Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST).Resolute Onyx DES provides enhanced visibility to surgeons, delivering superior clinical performance.
According to Medtronic, the RESOLUTE ONYX ONE-MONTH DAPT study aims to help inform DAPT guidelines for newer-generation DES that currently support bare-metal stents (BMS) for stable ischemic heart disease patients who might require a shorter dual antiplatelet regimen. The study will also demonstrate Medtronic’s clinical investment to provide relevant DAPT evidence to physicians for both current and previous generation DES.
DAPT therapy guidelines vary geographically as well as by patient presentation. Duration of DAPT evaluation is made based on individuals along with clinical judgment, evaluating the benefit/risk ratio, product labeling, and patient preference. The study will be based on approximately 2,000 patients worldwide.
As per the company’s press release, the RESOLUTE ONYX ONE-MONTH DAPT study outcomes will build on the RESOLUTE Pooled DAPT Interruption analysis that showed no increased risk of stent thrombosis with DAPT interruption or discontinuation after a month.
Taking into consideration the huge and growing global coronary stent market, we believe the latest initiative by Medtronic is well timed. Per a report by Transparency Market Research, the global coronary stents market is expected to see a CAGR of 6.6% from 2013 to 2019.
Recent Developments on Coronary Stent
Recently, Medtronic announced that DES has met its primary endpoint of Target Lesion Failure (TLF) at one year for the treatment of coronary artery disease in extra-small vessels.
Also, of late, the Resolute Onyx DES received FDA approval.Further, post the successful launch of Resolute Onyx DES in the U.S. in May 2017, Medtronic has started selling it in the Japan market from Jul 10, as per a Cardiovascular Business report released on Jul 7.
To note, over the last six months, Medtronic has outperformed the S&P 500 Index. As per the latest share price movement, the company has gained 7.2%, compared to the S&P 500’s 5.2% gain.
Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 2.7% over the last three months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 30.8% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 6.7% over the last three months.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study
Medical device major Medtronic plc (MDT - Free Report) is focusing on expanding its core Coronary and Structural Heart business. Keeping in line with this, the company recently announced a global randomized clinical trial to evaluate one-month dual antiplatelet therapy (DAPT) in patients implanted with the Resolute Onyx Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI) procedures.
DAPT is a combination of aspirin and anti-clotting medication. Notably, Resolute Onyx DES is the first DES which works on the Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST).Resolute Onyx DES provides enhanced visibility to surgeons, delivering superior clinical performance.
According to Medtronic, the RESOLUTE ONYX ONE-MONTH DAPT study aims to help inform DAPT guidelines for newer-generation DES that currently support bare-metal stents (BMS) for stable ischemic heart disease patients who might require a shorter dual antiplatelet regimen. The study will also demonstrate Medtronic’s clinical investment to provide relevant DAPT evidence to physicians for both current and previous generation DES.
DAPT therapy guidelines vary geographically as well as by patient presentation. Duration of DAPT evaluation is made based on individuals along with clinical judgment, evaluating the benefit/risk ratio, product labeling, and patient preference. The study will be based on approximately 2,000 patients worldwide.
As per the company’s press release, the RESOLUTE ONYX ONE-MONTH DAPT study outcomes will build on the RESOLUTE Pooled DAPT Interruption analysis that showed no increased risk of stent thrombosis with DAPT interruption or discontinuation after a month.
Taking into consideration the huge and growing global coronary stent market, we believe the latest initiative by Medtronic is well timed. Per a report by Transparency Market Research, the global coronary stents market is expected to see a CAGR of 6.6% from 2013 to 2019.
Recent Developments on Coronary Stent
Recently, Medtronic announced that DES has met its primary endpoint of Target Lesion Failure (TLF) at one year for the treatment of coronary artery disease in extra-small vessels.
Also, of late, the Resolute Onyx DES received FDA approval.Further, post the successful launch of Resolute Onyx DES in the U.S. in May 2017, Medtronic has started selling it in the Japan market from Jul 10, as per a Cardiovascular Business report released on Jul 7.
To note, over the last six months, Medtronic has outperformed the S&P 500 Index. As per the latest share price movement, the company has gained 7.2%, compared to the S&P 500’s 5.2% gain.
Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Lantheus Holdings carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 2.7% over the last three months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 30.8% over the last three months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 6.7% over the last three months.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>